Insight for practicing clinicians on targeted radionuclide therapies for prostate cancer
Scott T. Tagawa, MD, MS, FACP, discusses the current state of targeted radionuclide therapies in the prostate cancer paradigm and previews what’s on the horizon for the burgeoning field of theranostics. Tagawa is a professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Studies show low urinary bladder interference on flotufolastat F 18 scans
June 11th 2024“The ability to gather actionable information from PSMA PET scans is important for physicians to make informed decisions about patient management for men with prostate cancer,” says Eugene Teoh, MBBS, MRCP, FRCR, DPhil.
![[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Furologytimes%2F6583419a0719128d5ec70eb6a2f5729faf857b50-1200x905.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "[68Ga]Ga-PSMA-11 PET/CT shows value in initial staging of prostate cancer")
